Bryan Johnson· Author
my epigenetic speed of aging, organ epigenetic age, and methylome epigenetic biomarker proxies.
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
my epigenetic speed of aging, organ epigenetic age, and methylome epigenetic biomarker proxies.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
To assess efficacy for cellular, systemic, and brain rejuvenation, I will measure: + DNA methylation: speed of aging, organ ages, including the brain + telomere length and relative telomerase activity (RTA): the cells' capacity to regenerate telomeres + functional brain measurements: cortical activity and brain age via KernelFlow + blood proteomic panel: cellular senescence, brain aging, and rejuvenation markers + brain MRI: to measure structural changes, brain age, and potential rejuvenation + cognitive, mood, and psychological assessments to measure effects on mood and mental well-being + advanced blood biomarker panel: metabolic, inflammation, brain and neuronal health markers
We measure extensively. You can see here I'm about to get my blood drawn and I'm going to put on screen all of the tests we're going to do, but in all I suspect we probably have like a couple hundred biomarkers in total. We're casting a really wide net. Typically, people do studies, they say, "Does this thing affect that thing?" We're looking at a whole bunch of stuff from my brain to my DNA to my microbiome, all kinds of markers.